InMode Earnings Call: Growth Abroad, Margins Under Strain

Inmode ((INMD)) has held its Q4 earnings call. Read on for the main highlights of the call.

InMode’s latest earnings call struck a cautious but not pessimistic tone, as management balanced record international performance, growing consumables revenue and new product launches against declining full‑year sales, shrinking margins and sharply lower EPS. Executives presented 2026 as a stabilization year, betting that a richer product pipeline and a revamped commercial structure can offset macro and cost headwinds over time.

Q4 Revenue Beat Offers Some Near-Term Relief

InMode reported Q4 2025 revenue of $103.9 million, up 6.1% year over year from $97.9 million and slightly ahead of expectations. The sequential pickup suggests some traction exiting the year, even as the broader aesthetic market remains under pressure and full‑year results declined.

International Markets, Led by Europe, Drive Growth

International sales were the standout, reaching $48.5 million in Q4, up 38% year over year and equal to 47% of total revenue, with Europe posting a record quarter. For 2025, international revenue rose 15% to $171.8 million and represented 46% of total sales, helping offset weakness in North America.

Consumables and Services Show Early Signs of Stabilization

Consumables and services climbed to 22% of 2025 revenue, up from 20% in 2024, reflecting slightly higher procedure volumes and usage. Management pointed to roughly 128,000 consumable units sold as an early sign that procedure activity and recurring revenue are stabilizing even as system sales soften.

New Laser Platforms Expand the Product Pipeline

The company highlighted strong initial performance from its CO2 laser platforms launched in 2025 and reaffirmed its goal of introducing two new platforms annually. For 2026, InMode plans to roll out a Korean‑made Pico laser and a Morpheus plus Erbium YAG combination device, aiming to broaden its minimally invasive aesthetic portfolio.

Commercial Reorganization Targets Higher Productivity

Management detailed a major commercial reshuffle, naming Michael Dennison as President of North America and consolidating East, West and Canada into a single organization. The sales force is now segmented between aesthetic and wellness, with a dedicated Envision team created to deepen penetration and improve sales productivity across key product lines.

Robust Cash Pile Fuels Aggressive Buybacks

InMode ended 2025 with $555.3 million in cash, cash equivalents, marketable securities and deposits, underscoring a strong balance sheet. The company returned $127.4 million to shareholders through repurchases in 2025 and has bought back roughly $580 million over about two and a half years, supported by Q4 operating cash flow of $22.7 million.

High Gross Margins Hold, but Downward Pressure Looms

Non‑GAAP gross margin remained a lofty 79% in both Q4 and full‑year 2025, while GAAP gross margin was 78%, only slightly below 79% in 2024. Even so, management cautioned that sourcing more laser platforms externally and tariff costs could pull margins down toward the mid‑70s percentage range over time.

Full-Year Revenue Declines Highlight Industry Softness

Despite the strong finish to the year, 2025 revenue fell 6% to $370.5 million, reflecting a softer North American aesthetic market. Management tied the decline to industry‑wide weakness rather than company‑specific issues, aligning with reports of practitioners facing slower patient traffic.

Margin Compression Undercuts Profitability

Non‑GAAP operating margin slid to 26% for 2025 from 33% in 2024, while Q4 non‑GAAP operating margin declined to 27% from 32%. Looking ahead, the company guided 2026 non‑GAAP gross margin down to 75–77%, signaling further pressure on profitability as costs rise and product mix shifts.

GAAP EPS Drops Sharply as Earnings Reset

On a GAAP basis, diluted EPS fell to $0.42 in Q4 2025 from $1.14 a year earlier, while full‑year GAAP EPS dropped to $1.43 from $2.25, marking a significant reset in earnings power. Non‑GAAP diluted EPS also declined, slipping about 9% to $1.60 for 2025 from $1.76 in 2024.

Pricing and U.S. Systems Revenue Under Pressure

Average selling prices for platforms were down roughly 9% year over year in 2025, reflecting discounting and mix shifts. North American platform placements totaled about 2,100, roughly 100 fewer than in 2024, contributing to continued double‑digit declines in U.S. systems revenue.

Rising Operating Expenses and Cost Headwinds Weigh on Results

Non‑GAAP operating expenses rose 13.5% year over year in Q4 to $53.2 million and increased around 3.2% for the full year to $195.8 million, while GAAP operating expenses reached $205.6 million. Management cited higher costs tied to new products, commercial investments and external sourcing as key drivers behind the margin squeeze.

Macro and Industry Weakness Drag on Demand

Executives stressed that higher interest rates and cautious consumer spending continue to weigh on aesthetic procedure demand, particularly in North America. They also flagged potential demand shifts tied to GLP‑1 weight‑loss drugs, which could alter patient preferences and impact certain procedure categories.

Lower-Margin Mix and Tariffs Threaten Profit Structure

The company’s deliberate push into lasers such as Pico, Erbium and CO2 involves sourcing platforms externally, which carry lower gross margins than legacy systems. Combined with a 15% U.S. tariff on imports from Israel, these mix and cost factors are expected to pull gross margins closer to about 75% in coming periods.

Guidance: 2026 Framed as a Stabilization Year

For fiscal 2026, InMode forecast revenue of $365–$375 million, essentially flat versus 2025’s $370.5 million, with non‑GAAP gross margin easing to 75–77% and operating income of $87–$92 million. Non‑GAAP diluted EPS is projected at $1.43–$1.48, below 2025’s $1.60, signaling that management expects a year of consolidation focused on absorbing mix shifts and cost pressures while leveraging its cash strength and growing consumables base.

In sum, InMode’s earnings call painted a picture of a business under near‑term earnings pressure but not standing still, as international growth, recurring revenue and product innovation offset some of the strain from tariffs, pricing and weaker U.S. demand. Investors will be watching closely in 2026 to see whether the revamped commercial strategy and new platforms can turn this stabilization phase into a renewed growth cycle beyond next year.